Curated News
By: NewsRamp Editorial Staff
July 15, 2026

Regentis Biomaterials Gets Approval for Next-Gen GelrinC Manufacturing

Discuss on LinkedIn Discuss on X, formerly Twitter Discuss on Telegram participate in discussion on bluesky Participate in discussion on Mastodon View History of this news story on GitHub
Original Source

TLDR

  • Regentis's new solvent-free process boosts GelrinC yield 400%, gaining a competitive edge in the $3B U.S. cartilage repair market.
  • The next-generation manufacturing process eliminates solvents, increases production yield by 400%, and maintains consistent product quality validated by clinical tests.
  • Regentis's GelrinC regenerates cartilage via a 10-minute procedure, improving patient outcomes and reducing occupational and environmental hazards.
  • GelrinC is a cell-free hydrogel that gets resorbed by the body, allowing natural cartilage regeneration in a synchronized process.

Impact - Why it Matters

This milestone matters because it dramatically increases production capacity for GelrinC, a novel cartilage repair treatment that could offer a minimally invasive solution for the hundreds of thousands of patients suffering from knee cartilage damage. With no off-the-shelf alternatives currently available, this advancement brings Regentis closer to commercializing a therapy that may improve quality of life and reduce the need for more invasive surgeries, potentially transforming the orthopedic landscape.

Summary

Regentis Biomaterials (NYSE American: RGNT) has achieved a significant manufacturing milestone, receiving European Notified Body approval to produce its flagship product, GelrinC(R), using a next-generation solvent-free process. This innovation boosts production yield by approximately 400%, enabling five times more product from the same volume while enhancing efficiency, scalability, and safety. Extensive clinical testing confirms consistent quality and performance, paving the way for the product’s commercial launch in Europe. GelrinC(R), already CE Mark approved, is a cell-free hydrogel implant that regenerates cartilage via a minimally invasive 10-minute procedure. Regentis plans to support commercialization through its expanding European Centers of Excellence, surgeon training, and collaborations with leading institutions like Humanitas Research Hospital in Milan, targeting the U.S. cartilage repair market valued at around $3 billion.

GelrinC(R) addresses a critical need in orthopedic medicine: a market of approximately 470,000 annual U.S. cases of cartilage knee repair with no off-the-shelf treatment available. The hydrogel is designed to be eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled process. Regentis Biomaterials Ltd. is a regenerative medicine company focused on tissue repair solutions, with its Gelrin platform technology aimed at restoring damaged cartilage and bone. The company’s efforts are supported by a paid investor awareness campaign disseminated by BioMedWire (BMW), a specialized communications platform within the Dynamic Brand Portfolio of IBN. BMW provides press release distribution, editorial syndication to over 5,000 outlets, and social media reach to millions, helping companies like Regentis gain visibility among investors and the public.

For more details on this development, visit the full press release at https://ibn.fm/Ths4h. Investors can find the latest news on RGNT at https//ibn.fm/RGNT. BioMedWire (BMW) is powered by IBN and delivers breaking news and actionable information in the biotech and life sciences sectors.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Regentis Biomaterials Gets Approval for Next-Gen GelrinC Manufacturing

blockchain registration record for this content.